Skip to main content

Advertisement

Log in

Indian Society of Gastroenterology consensus on ulcerative colitis

  • TASK FORCE REPORT
  • Published:
Indian Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

In 2010, the Indian Society of Gastroenterology’s Task Force on Inflammatory Bowel Diseases undertook an exercise to produce consensus statements on ulcerative colitis. This consensus, produced through a modified Delphi process, reflects our current understanding of the definition, diagnostic work up, treatment and complications of ulcerative colitis. The consensus statements are intended to serve as a reference point for teaching, clinical practice, and research in India.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Makharia GK, Ramakrishna BS, Abraham P, et al. Survey of inflammatory bowel diseases in India. Indian J Gastroenterol. 2012;31: doi:10.1007/s12664-012-0258-1.

  2. Linstone H, Turoff M. The Delphi method: techniques and application. http://www.is.njit.edu/pubs/delphibook/. Accessed on August 15, 2012.

  3. Periodic health examination: 2. 1984 update. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J. 1984;130:1278–85.

    Google Scholar 

  4. Loftus EV Jr,. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504–17.

    Article  PubMed  Google Scholar 

  5. Khosla SN, Girdhar NK, Lal S, Mishra DS. Epidemiology of ulcerative colitis and select general population of northern India. J Assoc Physicians India. 1986;34:405–7.

    PubMed  CAS  Google Scholar 

  6. Sood A, Midha V, Sood N, et al. Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut. 2003;52:1587–90.

    Article  PubMed  CAS  Google Scholar 

  7. Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986–2005: a KASID study. Inflamm Bowel Dis. 2008;14:542–9.

    Article  PubMed  Google Scholar 

  8. Lok KH, Hung HG, Ng CH, et al. Epidemiology and clinical characteristics of ulcerative colitis in Chinese population: experience from a single center in Hong Kong. J Gastroenterol Hepatol. 2008;23:406–10.

    Article  PubMed  Google Scholar 

  9. Chow DK, Leong RW, Tsoi KK, et al. Long-term follow-up of ulcerative colitis in the Chinese population. Am J Gastroenterol. 2009;104:647–54.

    Article  PubMed  Google Scholar 

  10. Morita N, Toki S, Hirohashi T, et al. Incidence and prevalence of inflammatory bowel disease in Japan: nationwide epidemiological survey during the year 1991. J Gastroenterol. 1995;30 Suppl 8:1–4.

    Google Scholar 

  11. Lee YM, Fock K, See SJ, Ng TM, Khor C, Teo EK. Racial differences in the prevalence of ulcerative colitis and Crohn’s disease in Singapore. J Gastroenterol Hepatol. 2000;15:622–5.

    Article  PubMed  CAS  Google Scholar 

  12. Ling KL, Ooi CJ, Luman W, Cheong WK, Choen FS, Ng HS. Clinical characteristics of ulcerative colitis in Singapore, a multiracial city-state. J Clin Gastroenterol. 2002;35:144–8.

    Article  PubMed  Google Scholar 

  13. Tan YM, Goh KL. Ulcerative colitis in a multiracial Asian country: racial differences and clinical presentation among Malaysian patients. World J Gastroenterol. 2005;11:5859–62.

    PubMed  Google Scholar 

  14. Probert CS, Mayberry JF, Mann R. Inflammatory bowel disease in the rural Indian subcontinent: a survey of patients attending mission hospitals. Digestion. 1990;47:42–6.

    Article  PubMed  CAS  Google Scholar 

  15. Maroo MK, Nag NK, Sortur SV, Patil RS. Ulcerative colitis in Southern Maharashtra. J Indian Med Assoc. 1974;63:350–4.

    PubMed  CAS  Google Scholar 

  16. Tandon BN, Mathur AK, Mohapatra LN, Tandon HD, Wig KL. A study of the prevalence and clinical pattern of non-specific ulcerative colitis in northern India. Gut. 1965;6:448–53.

    Article  PubMed  CAS  Google Scholar 

  17. Sood A, Midha V. Epidemiology of inflammatory bowel disease in Asia. Indian J Gastroenterol. 2007;26:285–9.

    PubMed  Google Scholar 

  18. Satsangi J, Jewell DP, Rosenberg WM, Bell JI. Genetics of inflammatory bowel disease. Gut. 1994;35:696–700.

    Article  PubMed  CAS  Google Scholar 

  19. Jiang L, Xia B, Li J, et al. Risk factors for ulcerative colitis in a Chinese population: an age-matched and sex-matched case–control study. J Clin Gastroenterol. 2007;41:280–4.

    Article  PubMed  Google Scholar 

  20. Kitahora T, Utsunomiya T, Yokota A. Epidemiological study of ulcerative colitis in Japan: incidence and familial occurrence. The Epidemiology Group of the Research Committee of Inflammatory Bowel Disease in Japan. J Gastroenterol. 1995;30 Suppl 8:5–8.

    Google Scholar 

  21. Park JB, Yang SK, Byeon JS, et al. Familial occurrence of inflammatory bowel disease in Korea. Inflamm Bowel Dis. 2006;12:1146–51.

    Article  PubMed  Google Scholar 

  22. Probert CS, Jayanthi V, Hughes AO, Thompson JR, Wicks AC, Mayberry JF. Prevalence and family risk of ulcerative colitis and Crohn's disease: an epidemiological study among Europeans and south Asians in Leicestershire. Gut. 1993;34:1547–51.

    Article  PubMed  CAS  Google Scholar 

  23. Probert CS, Jayanthi V, Pinder D, et al. Epidemiological study of ulcerative proctocolitis in Indian migrants and the indigenous population of Leicestershire. Gut. 1992;33:687–93.

    Article  PubMed  CAS  Google Scholar 

  24. Carr I, Mayberry JF. The effects of migration on ulcerative colitis: a three-year prospective study among Europeans and first and second-generation South Asians in Leicester (1991–1994). Am J Gastroenterol. 1999;94:2918–22.

    PubMed  CAS  Google Scholar 

  25. Jayanthi V, Probert CS, Pollock DJ, et al. Low incidence of ulcerative colitis and proctitis in Bangladeshi migrants in Britain. Digestion. 1992;52:34–42.

    Article  PubMed  CAS  Google Scholar 

  26. Probert CS, Jayanthi V, Mayberry JF. Inflammatory bowel disease in Indian migrants in Fiji. Digestion. 1991;50:82–4.

    Article  PubMed  CAS  Google Scholar 

  27. Rajput HI, Seebaran AR, Desai Y. Ulcerative colitis in the Indian population of Durban. S Afr Med J. 1992;81:245–8.

    PubMed  CAS  Google Scholar 

  28. Kochhar R, Mehta SK, Nagi B, Bhatia V, Goenka MA, Malik AK. Extraintestinal manifestations in idiopathic ulcerative colitis. Indian J Gastroenterol. 1991;10:88–9.

    PubMed  CAS  Google Scholar 

  29. Pokharna RK, Kabra PK, Sharma P, Kochar DK. Extraintestinal manifestations of idiopatic ulcerative colitis in north western India. Indian J Gastroenterol. 2004;123:89–90.

    Google Scholar 

  30. Chandrasekaran AN, Porkodi R, Madhavan R, Sambandam PR, Jayanthi V, Ramathilagam B. Spectrum of clinical and immunological features of systemic rheumatic disorders in a referral hospital in south India: arthritis in ulcerative colitis. J Indian Rheumat Assoc. 1995;3:43–7.

    Google Scholar 

  31. Habeeb MA, Rajalingam R, Dhar A, Kumar A, Sharma MP, Mehra NK. HLA association and occurrence of autoantibodies in Asian patients with ulcerative colitis. Am J Gastroenterol. 1997;92:772–6.

    PubMed  CAS  Google Scholar 

  32. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology. Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371–85.

    Article  PubMed  Google Scholar 

  33. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53 Suppl 5:V1–16.

    Google Scholar 

  34. Stange EF, Travis SP, Vermeire S, et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn’s Colitis. 2008;2:1–23.

    Article  CAS  Google Scholar 

  35. Ooi CJ, Fock KM, Makharia GK, et al. The Asia-Pacific consensus on ulcerative colitis. J Gastroenterol Hepatol. 2010;25:453–68.

    Article  PubMed  CAS  Google Scholar 

  36. Tedesco FJ, Hardin RD, Harper RN, Edwards BH. Infectious colitis endoscopically simulating inflammatory bowel disease: a prospective evaluation. Gastrointest Endosc. 1983;29:195–7.

    Article  PubMed  CAS  Google Scholar 

  37. Dunzendorfer T, Kasznica J. Amebic and/or ulcerative colitis? Gastrointest Endosc. 1998;48:450–1.

    Article  PubMed  CAS  Google Scholar 

  38. Misra SP, Misra V, Dwivedi M, Singh PA. Colonic tuberculosis mimicking ulcerative colitis. J Assoc Physicians India. 1998;46:309–10.

    PubMed  CAS  Google Scholar 

  39. Chodos JE. Campylobacter infection mimicking ulcerative colitis. NY State J Med. 1986;86:22–3.

    CAS  Google Scholar 

  40. Ibrahim TM, Iheonunekwu N, Gill V, Vantapool H. Differentiating amoebic ulcero-haemorrhagic recto-colitis from idiopathic inflammatory bowel disease: still a diagnostic dilemma. West Indian Med J. 2005;54:210–12.

    Article  PubMed  CAS  Google Scholar 

  41. Mann EA, Saeed SA. Gastrointestinal infection as a trigger for inflammatory bowel disease. Curr Opin Gastroenterol. 2012;28:24–9.

    Article  PubMed  CAS  Google Scholar 

  42. Khuroo MS, Mahajan R, Zargar SA, et al. The colon in shigellosis: serial colonoscopic appearances in Shigella dysenteriae I. Endoscopy. 1990;22:35–8.

    Article  PubMed  CAS  Google Scholar 

  43. Kochhar R, Ayyagari A, Goenka MK, Dhali GK, Aggarwal R, Mehta SK. Role of infectious agents in exacerbations of ulcerative colitis in India. A study of Clostridium difficile. J Clin Gastroenterol. 1993;16:26–30.

    Article  PubMed  CAS  Google Scholar 

  44. Kishore J, Ghoshal U, Ghoshal UC, et al. Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. J Med Microbiol. 2004;53:1155–60.

    Google Scholar 

  45. Banerjee D, Deb R, Dar L, et al. High frequency of parasitic and viral stool pathogens in patients with active ulcerative colitis: report from a tropical country. Scand J Gastroenterol. 2009;44:325–31.

    Article  PubMed  Google Scholar 

  46. Roblin X, Pillet S, Oussalah A, et al. Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis. Am J Gastroenterol. 2011;106:2001–8.

    Article  PubMed  CAS  Google Scholar 

  47. Vaishnavi C, Kochhar R, Bhasin D, Thennarasu K, Singh K. Simultaneous assays for Clostridium difficile and faecal lactoferrin in ulcerative colitis. Trop Gastroenterol. 2003;24:13–6.

    PubMed  Google Scholar 

  48. Kashyap B, Sinha S, Das S, Rustagi N, Jhamb R. Efficiency of diagnostic methods for correlation between prevalence of enteric protozoan parasites and HIV/AIDS status––an experience of a tertiary care hospital in East Delhi. J Parasit Dis. 2010;34:63–7.

    Article  PubMed  Google Scholar 

  49. Montes M, Sawhney C, Barros N. Strongyloides stercoralis: there but not seen. Curr Opin Infect Dis. 2010;23:500–4.

    Article  PubMed  Google Scholar 

  50. Navarro-Llavat M, Domènech E, Bernal I, et al. Prospective, observational, cross-sectional study of intestinal infections among acutely active inflammatory bowel disease patients. Digestion. 2009;80:25–9.

    Article  PubMed  Google Scholar 

  51. Vaishnavi C. Clostridium difficile infection: clinical spectrum and approach to management. Indian J Gastroenterol. 2011;30:245–54.

    Article  PubMed  Google Scholar 

  52. Lawlor G, Moss AC. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander? Inflamm Bowel Dis. 2010;16:1620–7.

    Article  PubMed  Google Scholar 

  53. Sung JJY, Kamm MA, Marteau P. Asian perspectives in the management of inflammatory bowel disease: findings from a recent survey. J Gastroenterol Hepatol. 2010;25:183–93.

    Article  PubMed  Google Scholar 

  54. Schusselé Filliettaz S, Juillerat P, Burnand B, et al. Appropriateness of colonoscopy in Europe (EPAGE II). Chronic diarrhea and known inflammatory bowel disease. Endoscopy. 2009;41:218–26.

    Article  PubMed  Google Scholar 

  55. Louis E, Belaiche J, Reenaers C. Do clinical factors help to predict disease course in inflammatory bowel disease? World J Gastroenterol. 2010;16:2600–3.

    Article  PubMed  Google Scholar 

  56. Regueiro M, Loftus EV, Steinhart AH, Cohen RD. Medical management of left-sided ulcerative colitis and ulcerative proctitis: Critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006;12:979–94.

    Article  PubMed  Google Scholar 

  57. Kochhar R, Goenka MK, Kaushik SP, Gupta NM, Nagi B, Mehta SK. Colorectal carcinoma in Indian patients with idiopathic ulcerative colitis. Eur J Cancer Prev. 1992;1:293–6.

    Article  PubMed  CAS  Google Scholar 

  58. Venkataraman S, Mohan V, Ramakrishna BS, et al. Risk of colorectal cancer in ulcerative colitis in India. J Gastroenterol Hepatol. 2005;20:705–9.

    Article  PubMed  Google Scholar 

  59. Regueiro M, Rodemann J, Kip KE, et al. Physician assessment of ulcerative colitis activity correlates poorly with endoscopic disease activity. Inflamm Bowel Dis. 2011;17:1008–14.

    Article  PubMed  Google Scholar 

  60. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–53.

    Article  PubMed  CAS  Google Scholar 

  61. Naber AHJ, de Jong DJ. Assessment of disease activity in inflammatory bowel disease; relevance for clinical trials. Neth J Med. 2003;61:105–10.

    PubMed  CAS  Google Scholar 

  62. Thia KT, Loftus EV Jr, Pardi DS, et al. Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. Inflamm Bowel Dis. 2011;17:1257–64.

    Article  PubMed  Google Scholar 

  63. Bhatt J, Patil S, Joshi A, Abraham P, Desai D. Self-reported treatment adherence in inflammatory bowel disease in Indian patients. Indian J Gastroenterol. 2009;28:143–6.

    Article  PubMed  Google Scholar 

  64. Gionchetti P, Rizzello F, Morselli C, Tambasco R, Campieri M. Review article: aminosalicylates for distal colitis. Aliment Pharmacol Ther. 2006;24 Suppl 3:41–4.

    Google Scholar 

  65. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000;95:1263–76.

    Article  PubMed  CAS  Google Scholar 

  66. Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 1997;40:775–81.

    Article  PubMed  CAS  Google Scholar 

  67. Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;(1):CD004115.

  68. Campieri M, De Franchis R, Bianchi Porro G, et al. Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. Scand J Gastroenterol. 1990;25:663–8.

    Article  PubMed  CAS  Google Scholar 

  69. D’Arienzo A, Panarese A, D’Armiento FP, et al. 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial. Am J Gastroenterol. 1990;85:1079–82.

    PubMed  Google Scholar 

  70. Hanauer SB. Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The US PENTASA Enema Study Group. Inflamm Bowel Dis. 1998;4:79–83.

    Article  PubMed  CAS  Google Scholar 

  71. Biddle WL, Greenberger NJ, Swan JT, et al. 5-Aminosalicylic acid enemas: effective agent in maintaining remission in left -sided ulcerative colitis. Gastroenterology. 1988;94:1075–9.

    PubMed  CAS  Google Scholar 

  72. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(2):D000544.

  73. Baron JH, Connell AM, Lennard-Jones JE, et al. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet. 1962;1:1094–6.

    Article  PubMed  CAS  Google Scholar 

  74. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(2):CD000543.

  75. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2009;15:1–8.

    Article  PubMed  Google Scholar 

  76. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008;57:893–902.

    Article  PubMed  CAS  Google Scholar 

  77. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997;92:1867–71.

    PubMed  CAS  Google Scholar 

  78. Faubion Jr WA, Loftus Jr EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–60.

    Article  PubMed  CAS  Google Scholar 

  79. Truelove SC, Watkinson G, Draper G. Comparison of corticosteroid and SASP therapy in ulcerative colitis. Br Med J. 1962;2:1708–11.

    Article  PubMed  CAS  Google Scholar 

  80. Lennard-Jones JE, Longmore AJ, Newell AC, Wilson CWE, Avery Jones F. An assessment of prednisone, Salazopyrin and topicalhydrocortisone hemisuccinate used as outpatient treatment for ulcerative colitis. Gut. 1960;1:217–22.

    Article  PubMed  CAS  Google Scholar 

  81. Baron JH, Connell AM, Kanaghinis TG, et al. Outpatient treatment of ulcerative colitis: comparison between three doses of oral prednisone. Br Med J. 1962;2:441–3.

    Article  PubMed  CAS  Google Scholar 

  82. Rosenberg W, Ireland A, Jewell DP. High-dose methylprednisolone in the treatment of active ulcerative colitis. J Clin Gastroenterol. 1990;12:40–1.

    Article  PubMed  CAS  Google Scholar 

  83. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940–87.

    Article  PubMed  CAS  Google Scholar 

  84. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet. 1974;i:1067–70.

    Article  Google Scholar 

  85. Turner D, Walsh C, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103–10.

    Article  PubMed  CAS  Google Scholar 

  86. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47–53.

    Article  PubMed  CAS  Google Scholar 

  87. Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;(1):CD000478.

  88. Etchevers MJ, Aceituno M, Sans M. Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease. World J Gastroenterol. 2008;14:5512–8.

    Article  PubMed  CAS  Google Scholar 

  89. Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol. 1990;85:717–22.

    PubMed  CAS  Google Scholar 

  90. Leung Y, Panaccione R, Hemmelgarn B, Jones J. Exposing the weaknesses: a systematic review of azathioprine efficacy in ulcerative colitis. Dig Dis Sci. 2008;53:1455–61.

    Article  PubMed  CAS  Google Scholar 

  91. Sood A, Kaushal V, Midha V, Bhatia KL, Sood N, Malhotra V. The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol. 2002;37:270–4.

    Article  PubMed  CAS  Google Scholar 

  92. Hibi T, Naganuma M, Kitahora T, Kinjyo F, Shimoyama T. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol. 2003;38:740–6.

    Article  PubMed  CAS  Google Scholar 

  93. Sood A, Midha V, Sood N, Avasthi G. Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis. Indian J Gastroenterol. 2003;22:79–81.

    PubMed  Google Scholar 

  94. Sood A, Midha V, Sood N, Bansal M. Long term results of use of azathioprine in patients with ulcerative colitis in India. World J Gastroenterol. 2006;12:7332–6.

    PubMed  CAS  Google Scholar 

  95. Lichtenstein GR. Use of laboratory testing to guide 6-mercaptopurine/azathioprine therapy. Gastroenterology. 2004;127:1558–64.

    Article  PubMed  Google Scholar 

  96. Desire S, Balasubramanian P, Bajel A, et al. Frequency of TPMT alleles in Indian patients with acute lymphatic leukemia and effect on the dose of 6-mercaptopurine. Med Oncol. 2010;27:1046–9.

    Article  PubMed  CAS  Google Scholar 

  97. Kham SK, Tan PL, Tay AH, Heng CK, Yeoh AE, Quah TC. Thiopurine methyltransferase polymorphisms in a multiracial Asian population and children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2002;24:353–9.

    Article  PubMed  CAS  Google Scholar 

  98. Ashavaid TF, Raghavan R, Shah S, Kapadia A, Almel S, Desai D. TPMT and DPD polymorphisms: efficient screening method for Indian patients considering taking thiopurine and 5-FU drugs. Dis Markers. 2009;27:231–8.

    PubMed  CAS  Google Scholar 

  99. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–5.

    Article  PubMed  CAS  Google Scholar 

  100. Van Assche G, D’Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125:1025–31.

    Article  PubMed  Google Scholar 

  101. Sood A, Midha V, Sood N, et al. Cyclosporine in the treatment of severe steroid refractory ulcerative colitis: a retrospective analysis of 24 cases. Indian J Gastroenterol. 2008;27:232–5.

    PubMed  Google Scholar 

  102. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(3):CD005112.

  103. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–76.

    Article  PubMed  CAS  Google Scholar 

  104. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571–607.

    Article  PubMed  Google Scholar 

  105. Nordgaard-Lassen I, Dahlerup JF, Belard E, et al. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J. 2012;59:C4480.

    PubMed  Google Scholar 

  106. Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol. 2006;12:974–6.

    PubMed  Google Scholar 

  107. Colbert C, Chavarria A, Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. Inflamm Bowel Dis. 2007;13:1453–4.

    Article  PubMed  Google Scholar 

  108. Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat. 2008;15:89–102.

    PubMed  CAS  Google Scholar 

  109. Viazis N, Vlachogiannakos J, Georgiou O, et al. Course of inflammatory bowel disease in patients infected with human immunodeficiency virus. Inflamm Bowel Dis. 2010;16:507–11.

    PubMed  Google Scholar 

  110. Shale MJ, Seow CH, Coffin CS, Kaplan GG, Panaccione R, Ghosh S. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31:20–34.

    Article  PubMed  CAS  Google Scholar 

  111. Wilckens V, Kannengiesser K, Hoxhold K, Frenkel C, Kucharzik T, Maaser C. The immunization status of patients with IBD is alarmingly poor before the introduction of specific guidelines. Scand J Gastroenterol. 2011;46:855–61.

    Article  PubMed  Google Scholar 

  112. Pal S, Sahni P, Pande GK, Acharya SK, Chattopadhyay TK. Outcome following emergency surgery for refractory severe ulcerative colitis in a tertiary care centre in India. BMC Gastroenterol. 2005;5:39.

    Article  PubMed  Google Scholar 

  113. Cima RR. Timing and indications for colectomy in chronic ulcerative colitis: Surgical consideration. Dig Dis. 2010;28:501–7.

    Article  PubMed  Google Scholar 

  114. Van Assche G, Vermeire S, Rutgeerts P. Management of acute severe ulcerative colitis. Gut. 2011;60:130–3.

    Article  PubMed  CAS  Google Scholar 

  115. Travis S, Satsangi J, Lémann M. Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers. Gut. 2011;60:3–9.

    Article  PubMed  CAS  Google Scholar 

  116. Randall J, Singh B, Warren BF, Travis SP, Mortensen NJ, George BD. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg. 2010;97:404–9.

    Article  PubMed  CAS  Google Scholar 

  117. Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007;204:956–62.

    Article  PubMed  Google Scholar 

  118. Koltun WA. Role of medical rescue therapy in the management of acute severe ulcerative colitis: the surgical perspective. Expert Rev Gastroenterol Hepatol. 2009;3:325–7.

    Article  PubMed  Google Scholar 

  119. Andersson P, Söderholm JD. Surgery in ulcerative colitis: indication and timing. Dig Dis. 2009;27:335–40.

    Article  PubMed  Google Scholar 

  120. Rao YG, Saxena R, Sahni P, Pande GK, Chattopadhyay TK. Functional outcome and patient satisfaction after ileal pouch anal anastomosis for ulcerative colitis in a developing country. Trop Gastroenterol. 2002;23:66–9.

    PubMed  Google Scholar 

  121. Somashekar U, Gupta S, Soin A, Nundy S. Functional outcome and quality of life following restorative proctocolectomy for ulcerative colitis in Indians. Int J Colorectal Dis. 2010;25:967–73.

    Article  PubMed  Google Scholar 

  122. Odze RD. Adenomas and adenoma-like DALMs in chronic ulcerative colitis: a clinical, pathological, and molecular review. Am J Gastroenterol. 1999;94:1746–50.

    Article  PubMed  CAS  Google Scholar 

  123. Vleggaar FP, Lutgens MW, Claessen MM. Review article: the relevance of surveillance endoscopy in long-lasting inflammatory bowel disease. Aliment Pharmacol Ther. 2007;26 Suppl 2:47–52.

    Google Scholar 

  124. Thomas T, Nair P, Dronfield MW, Mayberry JF. Management of low and high-grade dysplasia in inflammatory bowel disease: the gastroenterologists' perspective and current practice in the United Kingdom. Eur J Gastroenterol Hepatol. 2005;17:1317–24.

    Article  PubMed  Google Scholar 

  125. Eaden JA, Mayberry JF. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut. 2002;51 Suppl 5:V10–12.

    Google Scholar 

  126. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:795–841.

    Article  PubMed  Google Scholar 

  127. Loftus EV Jr, Achenbach SJ, Sandborn WJ, Tremaine WJ, Oberg AL, Melton LJ 3rd. Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2003;1:465–73.

    Article  PubMed  Google Scholar 

  128. Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol. 2002;156:1–10.

    Article  PubMed  Google Scholar 

  129. Ezzat Y, Hamdy K. The frequency of low bone mineral density and its associated risk factors in patients with inflammatory bowel diseases. Int J Rheum Dis. 2010;13:259–65.

    Article  PubMed  Google Scholar 

  130. Navaneethan U, Shen L, Venkatesh PG, et al. Influence of ileal pouch anal anastomosis on bone loss in ulcerative colitis patients. J Crohns Colitis. 2011;5:415–22.

    Article  PubMed  Google Scholar 

  131. Shen B, Remzi FH, Oikonomou IK, et al. Risk factors for low bone mass in patients with ulcerative colitis following ileal pouch-anal anastomosis. Am J Gastroenterol. 2009;104:639–46.

    Article  PubMed  Google Scholar 

  132. Khadgawat R, Makharia GK, Puri K. Evaluation of bone mineral density among patients with inflammatory bowel disease in a tertiary care setting in India. Indian J Gastroenterol. 2008;27:103–6.

    PubMed  Google Scholar 

  133. Jowett SL, Seal CJ, Phillips E, Gregory W, Barton JR, Welfare MR. Dietary beliefs of people with ulcerative colitis and their effect on relapse and nutrient intake. Clin Nutr. 2004;23:161–70.

    Article  PubMed  Google Scholar 

  134. Bernstein CN, Ament M, Artinian L, Ridgeway J, Shanahan F. Milk tolerance in adults with ulcerative colitis. Am J Gastroenterol. 1994;89:872–7.

    PubMed  CAS  Google Scholar 

  135. Chaves S, Perdigon G, de Moreno de LeBlanc A. Yoghurt consumption regulates the immune cells implicated in acute intestinal inflammation and prevents the recurrence of the inflammatory process in a mouse model. J Food Prot. 2011;74:801–11.

    Article  PubMed  CAS  Google Scholar 

  136. Elahi B, Nikfar S, Derakhshani S, Vafaie M, Abdollahi M. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. Dig Dis Sci. 2008;53:1278–84.

    Article  PubMed  Google Scholar 

  137. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999;354:635–9.

    Article  PubMed  CAS  Google Scholar 

  138. Mallon P, McKay D, Kirk S, Gardiner K. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;(4):CD005573.

  139. Do VT, Baird BG, Kockler DR. Probiotics for maintaining remission of ulcerative colitis in adults. Ann Pharmacother. 2010;44:565–71.

    Article  PubMed  Google Scholar 

  140. Jonkers D, Penders J, Masclee A, Pierik M. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs. 2012;72:803–23.

    Article  PubMed  Google Scholar 

  141. Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:1202–9.

    Article  PubMed  Google Scholar 

  142. Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut. 2007;56:830–7.

    Article  PubMed  CAS  Google Scholar 

  143. Uribe M, Chavez-Tapia NC, Mendez-Sanchez N. Pregnancy and autoimmune hepatitis. Ann Hepatol. 2006;5:187–9.

    PubMed  CAS  Google Scholar 

  144. Warrell DW, Taylor R. Outcome for the foetus of mothers receiving prednisolone during pregnancy. Lancet. 1968;1:117–8.

    Article  PubMed  CAS  Google Scholar 

  145. Ham M, Moss AC. Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol. 2012;5:113–23.

    Article  PubMed  CAS  Google Scholar 

  146. Schirbel A, Sturm A. Imaging in inflammatory bowel disease: mucosal healing in ulcerative colitis: relevance for clinical outcomes. Curr Drug Targets. 2012; May 28. [Epub ahead of print].

  147. Hanauer SB. Review article: the long-term management of ulcerative colitis. Aliment Pharmacol Ther. 2004;20 Suppl 4:97–101.

    Article  PubMed  Google Scholar 

  148. Stolfi C, Pellegrini R, Franze E, Pallone F, Monteleone G. Molecular basis of the potential of mesalazine to prevent colorectal cancer. World J Gastroenterol. 2008;14:4434–9.

    Article  PubMed  CAS  Google Scholar 

  149. Levine JS, Burakoff R. Chemoprophylaxis of colorectal cancer in inflammatory bowel disease: current concepts. Inflamm Bowel Dis. 2007;13:1293–8.

    Article  PubMed  Google Scholar 

  150. Ullman T, Croog V, Harpaz N, et al. Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine. Clin Gastroenterol Hepatol. 2008;6:1225–30.

    Article  PubMed  CAS  Google Scholar 

  151. Bernstein CN, Nugent Z, Blanchard JF. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol. 2011;106:731–6.

    Article  PubMed  CAS  Google Scholar 

  152. Ardizzone S, Porro GB. How long is it advisable to prolong maintenance treatment of patients with ulcerative colitis? Inflamm Bowel Dis. 2008;14 Suppl 2:S238–9.

    Article  PubMed  Google Scholar 

  153. Kamm MA. Review article: maintenance of remission in ulcerative colitis. Aliment Pharmacol Ther. 2002;16 Suppl 4:21–4.

    Article  PubMed  Google Scholar 

  154. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(2):CD000544.

Download references

Acknowledgements

We acknowledge and deeply appreciate the participation and contribution of Kshaunish Das, Surinder S Rana, and Vandana Midha in the voting process.

Funding Source

Unrestricted educational grant to the Society for this Task Force activity from Sun Pharmaceuticals.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Balakrishnan S. Ramakrishna.

Additional information

Authors’ participation

Members who participated in the all three phases of voting including face to face meeting held in Mumbai from October 8–9, 2010

Balakrishnan S Ramakrishna, Govind K Makharia, Philip Abraham, Uday C Ghoshal, Venkataraman Jayanthi, Shobna J Bhatia, Sunil Dadhich, Devendra C Desai, Bhaba Dev Goswami, Sanjeev K Issar, Ajay Jain, Goundappa Loganathan, Sri Prakash Misra, C Ganesh Pai, Sujoy Pal, Anna Pulimood, Amarender S Puri, Gautam Ray, Shivaram P Singh

Members who participated only in voting 1 and voting 2

Brij Kishore Agarwal, Vineet Ahuja, Deepak K Bhasin, Gourdas Choudhuri, Gopal Krishna Dhali, Rakesh Kochhar, Ajay Kumar, G N Ramesh, Ajit Sood, Manu Tandan

See editorial on DOI:10.1007/s12664-012-0266-1

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ramakrishna, B.S., Makharia, G.K., Abraham, P. et al. Indian Society of Gastroenterology consensus on ulcerative colitis. Indian J Gastroenterol 31, 307–323 (2012). https://doi.org/10.1007/s12664-012-0259-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12664-012-0259-0

Keywords

Navigation